Table 2

Number of auto-antibody positive/negative patients at baseline and on treatment

AutoantibodiesBaseline (positive/total)OnTx (positive/total)Positive → negativeNegative → positiveDouble-positiveDouble-negative
RF10/143 (6.99%)10/143 (6.99%)337130
CCP20/143 (0%)0/143 (0%)0000
Anti-Tg7/143 (4.90%)22/143 (15.4%)0157121
Anti-TPO7/143 (4.90%)12/143 (8.39%)166130
ANA19/143 (13.3%)17/143 (11.9%)4215122
Total37/143 (25.9%)45/143 (31.5%)5133293
  • ANA, antinuclear antibodies; anti-Tg, anti-thyroglobulin antibodies; anti-TPO, anti-thyroid peroxidase antibodies; CCP2, anti-cyclic citrullinated peptide antibodies; OnTx, autoantibodies developed during treatment with anti-PD1; RF, rheumatoid factor.